South & Central America Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays, Radioimmunoassays, and Others), Clinical Indication, and End User

List of Tables

The South & Central America immunodiagnostics market is expected to grow from US$ 955.72 million in 2023 to US$ 1,648.52 million by 2030. It is estimated to grow at a CAGR of 8.1% from 2023 to 2030.

Increasing Prevalence of Infectious Diseases Drive South & Central America Industrial Robotics Market

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests.

Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide.

Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.

TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.

According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.

Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.

South & Central America Immunodiagnostics Market Overview

According to World Population Ageing 2019 report, the number of people aged above 65 years was 19.526 million in Brazil in 2019 and is expected to reach 52.026 million by 2050. This increase in the geriatric population is expected to raise the country's prevalence rate of liver, colon, and pancreatic cancer since older people are more prone to these cancers, as well as other chronic diseases, which would subsequently boost the demand for diagnostics. Large outbreaks of bacterial and viral pandemics, increasing demand for point-of-care diagnostics, and rapidly evolving technology are further propelling the growth of molecular diagnostics. For instance, in November 2020, Chembio Diagnostics, Inc., a leading point-of-care diagnostic company focused on infectious diseases, revealed that its subsidiary Chembio Diagnostics Brazil Ltda received Agencia Nacional de Vigilancia Sanitaria (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system in Brazil. In Brazil, NCDs also constitute a health problem of a large magnitude and account for 72% of causes of death, especially cardiovascular diseases (31.3%), cancer (16.3%), diabetes (5.2%), and chronic respiratory disease (5.8%). Thus, the rising cases of cancer, diabetes, and other chronic diseases is surging the demand for immunodiagnostics.

South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Immunodiagnostics Market Segmentation

The South & Central America immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the South & Central America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the South & Central America immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the South & Central America immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the South & Central America immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the South & Central America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the South & Central America immunodiagnostics market.

Based on country, the South & Central America immunodiagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2023, the Rest of South & Central America segment registered the largest share in the South & Central America immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the South & Central America immunodiagnostics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America immunodiagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00027836

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 South & Central America Immunodiagnostics Market - by Product
- 1.3.2 South & Central America Immunodiagnostics Market - by Clinical Indication
- 1.3.3 South & Central America Immunodiagnostics Market - by End User
- 1.3.4 South & Central America Immunodiagnostics Market - by Country

2. South & Central America Immunodiagnostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Immunodiagnostics Market - Market Landscape

4.1 Overview
4.2 South & Central America PEST Analysis
4.3 Expert's Opinion

5. South & Central America Immunodiagnostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Infectious Diseases
- 5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
- 5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
- 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
- 5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis

6. Immunodiagnostics Market - South & Central America Analysis

6.1 South & Central America Immunodiagnostics Market Revenue Forecast and Analysis

7. South & Central America Immunodiagnostics Market Analysis - by Product

7.1 Overview
7.2 South & Central America Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
- 7.3.1 Overview
- 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
- 7.4.1 Overview
- 7.4.2 Chemiluminescence Immunoassays (CLIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.3 Vitamin D Assay
  - 7.4.3.1 Overview
  - 7.4.3.2 Vitamin D Assay: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.4 HIV Detection
  - 7.4.4.1 Overview
  - 7.4.4.2 HIV Detection: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.5 HIV Ag/Ab Combo assay
  - 7.4.5.1 Overview
  - 7.4.5.2 HIV Ag/Ab Combo Assay: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.6 Other Tests
  - 7.4.6.1 Overview
  - 7.4.6.2 Other Tests: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
- 7.5.1 Overview
- 7.5.2 Radioimmunoassays (RIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Immunodiagnostics Market Analysis - Clinical Indication

8.1 Overview
8.2 South & Central America Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
- 8.3.1 Overview
- 8.3.2 Infectious Diseases: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 COVID-19
    - 8.3.2.1.1 Overview
    - 8.3.2.1.2 COVID-19: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Tuberculosis
    - 8.3.2.2.1 Overview
    - 8.3.2.2.2 Tuberculosis: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.3 Lyme
    - 8.3.2.3.1 Overview
    - 8.3.2.3.2 Lyme: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.4 Infection Management
    - 8.3.2.4.1 Overview
    - 8.3.2.4.2 Infection Management: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.5 Zika
    - 8.3.2.5.1 Overview
    - 8.3.2.5.2 Zika: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.6 Treponema
    - 8.3.2.6.1 Overview
    - 8.3.2.6.2 Treponema: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.7 TORCH
    - 8.3.2.7.1 Overview
    - 8.3.2.7.2 TORCH: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.8 Measles and Mumps
    - 8.3.2.8.1 Overview
    - 8.3.2.8.2 Measles and Mumps: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.9 VZV
    - 8.3.2.9.1 Overview
    - 8.3.2.9.2 VZV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.10 EBV
    - 8.3.2.10.1 Overview
    - 8.3.2.10.2 EBV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
- 8.4.1 Overview
- 8.4.2 Hepatitis+HIV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
- 8.5.1 Overview
- 8.5.2 Gastrointestinal: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolics: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
- 8.7.1 Overview
- 8.7.2 Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.3 Hypertension
  - 8.7.3.1 Overview
  - 8.7.3.2 Hypertension: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.4 Growth
  - 8.7.4.1 Overview
  - 8.7.4.2 Growth: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.5 Diabetes
  - 8.7.5.1 Overview
  - 8.7.5.2 Diabetes: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.6 Thyroid
  - 8.7.6.1 Overview
  - 8.7.6.2 Thyroid: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.7 Reproductive Endocrinology
  - 8.7.7.1 Overview
  - 8.7.7.2 Reproductive Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Immunodiagnostics Market Analysis - End User

9.1 Overview
9.2 South & Central America Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
- 9.4.1 Overview
- 9.4.2 Clinics: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
- 9.5.1 Overview
- 9.5.2 Diagnostic Laboratories: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
- 9.6.1 Overview
- 9.6.2 Academic and Research Institutes: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Immunodiagnostics Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview

11. South & Central America Immunodiagnostics Market -Industry Landscape

11.1 Overview
11.2 Growth Strategies in the South & Central America immunodiagnostics market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 DiaSorin SpA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Danaher Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 PerkinElmer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 bioMerieux SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Svar Life Science AB
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms